Allianz Asset Management
TCRT icon

Allianz Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Allianz Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-70
Closed -$27K – 1948
2020
Q3 		$27K Sell
70
-49
-41% -$21.6K ﹤0.01% 1826
2020
Q2 		$58K Sell
119
-1,263
-91% -$563K ﹤0.01% 2359
2020
Q1 		$508K Buy
1,382
+10
+0.7% +$5.17K ﹤0.01% 2058
2019
Q4 		$971K Buy
1,372
+63
+5% +$43.4K ﹤0.01% 2216
2019
Q3 		$840K Buy
+1,309
New +$1.04M ﹤0.01% 2194

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Allianz Asset Management's TCRT Position: Q4 2020 in Review

Allianz Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2020, closing a stake of 70 shares — an estimated $27K sold.

Allianz Asset Management first reported a position in TCRT in Q3 2019 and held it in 5 quarters. The position peaked at $971K in Q4 2019. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

  • Allianz Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Allianz Asset Management sold 70 Alaunos Therapeutics shares in Q4 2020, an estimated $27K.
  • Allianz Asset Management first reported a position in Alaunos Therapeutics in Q3 2019 and held it in 5 quarters.
  • Allianz Asset Management's Alaunos Therapeutics position peaked at $971K in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on Allianz Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.